Search
BIOAGE Labs Inc
BIOAAdd to Watchlist
10.600USD
+0.170+1.63%
Close 08-14 16:00（ET）Quotes delayed by 15 min
485.24MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of BIOAGE Labs Inc is 8.44, ranking 127 out of 387 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 15.00 and a low of 9.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
35.625
Target Price
+241.56%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
BIOAGE Labs Inc
BIOA
9
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is BIOAGE Labs Inc's expected revenue for the next quarter?
BIOAGE Labs Inc's expected revenue is 1.73M.
What is BIOAGE Labs Inc's price target?
Analysts forecast that BIOAGE Labs Inc's price target is USD 12.00, with the highest forecast at USD 15.00 and the lowest forecast at USD 9.00.
How have BIOAGE Labs IncBIOA's recent earnings per share performed?
The market expectation was USD -0.58, while BIOAGE Labs IncBIOA's earnings per share (EPS) for the previous quarter was USD -0.52. EPS for the next quarter is expected at USD -0.50.
What is the analyst rating for BIOAGE Labs Inc?
Based on the ratings of BIOAGE Labs Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.